| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/SJ.ONC.1207456 |
| P698 | PubMed publication ID | 14981546 |
| P2093 | author name string | James D Griffin | |
| Hai T Ngo | |||
| Hyun Kang | |||
| Blanca Scheijen | |||
| P2860 | cites work | Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor | Q22009126 |
| Direct control of the Forkhead transcription factor AFX by protein kinase B | Q22009452 | ||
| AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 | Q22254000 | ||
| Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis | Q24310597 | ||
| The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans | Q28131830 | ||
| Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity | Q28138855 | ||
| Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1 | Q28142184 | ||
| FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer | Q28204251 | ||
| The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2 | Q28216784 | ||
| A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo | Q28217482 | ||
| Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt | Q28255373 | ||
| Regulation of cell death protease caspase-9 by phosphorylation | Q28288607 | ||
| p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 | Q28505037 | ||
| Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release | Q28567073 | ||
| Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a | Q28592736 | ||
| Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B | Q28638147 | ||
| The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase | Q29618387 | ||
| Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). | Q33606105 | ||
| Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. | Q34139532 | ||
| Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis | Q34523534 | ||
| Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease | Q34658532 | ||
| The roles of FLT3 in hematopoiesis and leukemia | Q34784925 | ||
| FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity | Q36324207 | ||
| Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling | Q36368800 | ||
| A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells | Q40686902 | ||
| Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations | Q40695014 | ||
| TEL/platelet-derived growth factor receptor beta activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle | Q40748760 | ||
| FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model | Q40760923 | ||
| Insulin regulation of gene expression through the forkhead transcription factor Foxo1 (Fkhr) requires kinases distinct from Akt. | Q40778709 | ||
| BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. | Q40809849 | ||
| Forkhead family transcription factor FKHRL1 is expressed in human megakaryocytes. Regulation of cell cycling as a downstream molecule of thrombopoietin signaling | Q40817308 | ||
| In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor | Q40893632 | ||
| Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells | Q41149851 | ||
| Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia | Q42169557 | ||
| Forkhead transcription factors contribute to execution of the mitotic programme in mammals | Q42824525 | ||
| Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia | Q43665962 | ||
| A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia | Q44182964 | ||
| Negative regulation of the forkhead transcription factor FKHR by Akt. | Q52535267 | ||
| Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. | Q53399561 | ||
| Essential role for the BH3-only protein Bim but redundant roles for Bax, Bcl-2, and Bcl-w in the control of granulocyte survival | Q62817743 | ||
| Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines | Q73501441 | ||
| Activation of the Akt/FKHRL1 pathway mediates the antiapoptotic effects of erythropoietin in primary human erythroid progenitors | Q74177531 | ||
| BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1) | Q74355628 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3338-3349 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins | |
| P478 | volume | 23 |
| Q64256227 | , a Treasured Medicinal Mushroom, Induces Growth Arrest in Breast Cancer Cells, T47D Cells: New Mechanisms Emerge |
| Q48721287 | A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program |
| Q41973517 | A potential therapeutic target for FLT3-ITD AML: PIM1 kinase |
| Q37312735 | ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside |
| Q104586163 | AKT phosphorylates FOXO3 downstream of FLT3 |
| Q104586164 | AKT-phosphorylated FOXO3 translocates to cytosol |
| Q27027207 | An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment |
| Q39907753 | BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. |
| Q37724957 | Bench to bedside targeting of FLT3 in acute leukemia |
| Q97525450 | Cabozantinib, a Multityrosine Kinase Inhibitor of MET and VEGF Receptors Which Suppresses Mouse Laser-Induced Choroidal Neovascularization |
| Q40270156 | Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner |
| Q42729095 | Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation |
| Q24303657 | Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation |
| Q60149868 | Critical role of FOXO3a in carcinogenesis |
| Q40462629 | Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. |
| Q40165118 | Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. |
| Q24617091 | Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications |
| Q37771863 | Drug resistance in mutant FLT3-positive AML. |
| Q36407425 | Emerging Flt3 kinase inhibitors in the treatment of leukaemia |
| Q39957768 | Evidence for AKT-independent regulation of FOXO1 and FOXO3 in haematopoietic stem and progenitor cells |
| Q39513601 | FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations |
| Q37810061 | FLT3 inhibitors in acute myeloid leukemia |
| Q36183556 | FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia |
| Q54243631 | FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia. |
| Q39282600 | FLT3-ITD and its current role in acute myeloid leukaemia |
| Q41377055 | FOXO Signaling Pathways as Therapeutic Targets in Cancer |
| Q38674456 | FOXO transcription factors in cancer development and therapy |
| Q46443231 | FOXO3 Transcription Factor Is Essential for Protecting Hematopoietic Stem and Progenitor Cells from Oxidative DNA Damage |
| Q104586165 | FOXO3-dependent BCL2L11 gene expression |
| Q104586167 | FOXO3-dependent CDKN1B gene expression |
| Q35934174 | Forkhead-box transcription factors and their role in the immune system |
| Q36334327 | FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis |
| Q36065874 | Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia |
| Q34591403 | Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens |
| Q50514234 | Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice. |
| Q37809866 | Molecular diagnosis of acute myeloid leukemia |
| Q36461618 | Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. |
| Q36508937 | Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells |
| Q37390575 | Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors |
| Q51065084 | Remarkably reduced expression of FoxO3a in metaplastic colorectum, primary colorectal cancer and liver metastasis. |
| Q33790284 | Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors |
| Q37642294 | Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q36251180 | Signal transduction of oncogenic Flt3. |
| Q28477934 | Survey of activated FLT3 signaling in leukemia |
| Q46944998 | Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway |
| Q99549077 | Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence |
| Q104495182 | Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy |
| Q34173253 | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway |
| Q33838356 | The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis |
| Q58699279 | The Myc/Max/Mxd Network Is a Target of Mutated Flt3 Signaling in Hematopoietic Stem Cells in Flt3-ITD-Induced Myeloproliferative Disease |
| Q92989510 | The Role of Forkhead Box Proteins in Acute Myeloid Leukemia |
| Q28253741 | The emerging roles of forkhead box (Fox) proteins in cancer |
| Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |
| Q34636735 | Treatment of FLT3-ITD acute myeloid leukemia. |
| Q40435143 | Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases |
| Q41866183 | Up a lymphoid blind alley: Does CALM/AF10 disturb Ikaros during leukemogenesis? |
| Q34972224 | Wnt/β-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3β Dependent Manner |
| Q92459714 | circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression |
| Q42341693 | p27 in FLT3-driven acute myeloid leukemia: many roads lead to ruin. |
| Q35485832 | p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12. |
Search more.